Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,121.90INR
3:40pm IST
Change (% chg)

Rs-14.40 (-0.67%)
Prev Close
Rs2,136.30
Open
Rs2,130.00
Day's High
Rs2,145.95
Day's Low
Rs2,106.05
Volume
267,337
Avg. Vol
557,352
52-wk High
Rs2,787.00
52-wk Low
Rs1,901.15

Select another date:

Tue, Apr 10 2018

BRIEF-Dr.Reddy's Laboratories Gets EIR From US FDA For API Cuernavaca Plant In Mexico

* SAYS GETS EIR FROM US FDA FOR API CUERNAVACA PLANT IN MEXICO Source text: https://bit.ly/2H9URmM Further company coverage:

BUZZ-CY 2018 to be volatile for Indian stock markets - Citi

** Calendar year 2018 will be volatile for Indian stock markets, says Citi

BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate

* CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE

BRIEF-Dr.Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer

* CHIEF OPERATING OFFICER ABHIJIT MUKHERJEE TO RETIRE ON MARCH 31

BRIEF-Dr.Reddy's Labs Gets Form 483 With 4 Observations For API Hyderabad Plant Audit

* SAYS AUDIT OF API HYDERABAD PLANT IN TELENGANA BY U.S. FDA COMPLETED ON MARCH 16

BRIEF-Dr.Reddy's Laboratories Launches Levocetirizine Dihydrochloride Tablets USP, 5 Mg In U.S.

* ANNOUNCES LAUNCH OF LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS USP, 5 MG IN U.S. MARKET Source text - http://bit.ly/2FUOwea Further company coverage:

BRIEF-India's Dr.Reddy's Laboratories Gets 5 Observations From U.S FDA For API Unit At Hyderabad ‍​

* U.S FDA ISSUES FORM 483 WITH 5 OBSERVATIONS FOR API UNIT AT HYDERABAD ‍​ Source text - http://bit.ly/2IehGDn Further company coverage:

BRIEF-Dr.Reddy's Laboratories Says Amended Complaint w.r.t U.S. Class Action Lawsuit Filed

* W.R.T U.S. CLASS ACTION LAWSUIT, AMENDED COMPLAINT FILED BY PLAINTIFF WHERE CHAIRMAN, COO AND U.S. UNIT ADDED AS DEFENDANTS Source text - http://bit.ly/2CvdcnN Further company coverage:

BRIEF-Dr.Reddy's Lab Announces Launch Of Tetrabenazine Tablets In U.S. Market

* SAYS ANNOUNCEMENT OF LAUNCH OF TETRABENAZINE TABLETS IN U.S. MARKET Source text - http://bit.ly/2GH4t5d Further company coverage:

Dr. Reddy's Q3 profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr. Reddy's Laboratories Ltd said quarterly net profit slumped nearly 40 percent, its third consecutive quarter of declines as pricing pressures in the United States hit sales.

Select another date: